Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis-Reference-Cited by-同舟云学术

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis

Published:2016-03-22 Issue:9 Volume:51 Page:1062-1068
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Keil Radan¹,Wasserbauer Martin¹,Zádorová Zdena²,Hajer Jan²,Drastich Pavel³,Wohl Pavel³,Beneš Marek³,Bojková Martina⁴,Svoboda Pavel⁴,Konečný Michal⁵,Falt Přemysl⁶,Vaňásek Tomáš⁷,Pešta Martin⁸,Pešek František⁹,Bouchner Luděk⁹,Koželuhová Jana¹⁰,Novotný Aleš¹⁰,Bartůsková Lucie¹¹,Špičák Julius³

Affiliation:

1. Department of Internal Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic;

2. 2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University in Prague, FNKV, Prague, Czech Republic;

3. Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;

4. Clinic of Internal Medicine, University Hospital Ostrava, Ostrava, Czech Republic;

5. 2nd Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic;

6. Digestive Diseases Center, Vítkovice Hospital, Ostrava, Czech Republic;

7. 2nd Department of Internal Medicine-Gastroenterology, University Hospital Hradec Králové, Hradec Králové, Czech Republic;

8. Department of Internal Medicine, Hospital Na Bulovce, Prague, Czech Republic;

9. 2nd Department of Internal Medicine, University Hospital Plzeň-Bory, Plzeň, Czech Republic;

10. 4th Department of Internal Medicine – Clinic of Gastroenterology and Hepatology, The General University Hospital in Prague, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic;

11. Department of Economic and Social Policy, University of Economics, Prague, Czech Republic

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.3109/00365521.2016.1149883

Reference36 articles.

1. Feldman M, Friedman L, Bramdt L. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 9th ed. Philadelphia (PA): Elsevier; 2010. p. 1941–2013.

2. Baumgart D. Crohn’s disease and ulcerative colitis from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. 1st ed. New York (NY): Springer; 2012. p. 3–74.

3. Review article: infliximab therapy for inflammatory bowel disease - seven years on

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Infliximab for maintenance of medically-induced remission in Crohn's disease;Cochrane Database of Systematic Reviews;2024-02-19

3. Therapeutic potential and mechanism of functional oligosaccharides in inflammatory bowel disease: a review;Food Science and Human Wellness;2023-11

4. Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring;PLOS ONE;2022-08-08

5. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy;Expert Opinion on Biological Therapy;2021-12-27